A new research report titled “Global Markets for Asthma & COPD Drugs” from RnRMarketResearch.com projects that the global market for prescription asthma and COPD drugs will rise from almost $35 billion in 2011 to $38 billion in 2012 and just over $47 billion in 2017.
The report predicts that asthma drug sales alone will reach $20.2 billion in 2017, up from $15.3 billion in 2012 and that COPD drugs will rise from $5.3 billion in 2012 to $5.6 billion in 2017. The remaining increase comes from combination asthma/COPD drugs.
Read the RnRMarketResearch.com press release.
